由金融界主办的"启航·2025金融峰会"于12月26日在北京成功举办，本届大会以"新开局、新动能、新征程"为主题，汇聚监管部门、行业协会、金 融机构、上市公司、媒体等数百位相关领导和重磅嘉宾。作为大会备受关注的重要成果，第十四届"金智奖"年度评选结果正式揭晓，思路迪医药 （股票代码：1244.HK）荣获"医药生物产业优胜奖"。 作为深耕肿瘤慢病化治疗领域的创新药企，思路迪医药自 2014 年成立以来始终以 "帮助肿瘤患者活得更久更好" 为愿景，秉持 "以临床需求为导 向" 核心战略，其首款商业化产品恩维达 ®（恩沃利单抗）作为全球首个皮下注射 PD-L1 抑制剂，已造福数万患者，并累积超17亿营业收入。同 时公司继续构建了包括In vivo CAR-T/NK、mRNA-LNP肿瘤疫苗、核药三大技术开发平台。通用型 mRNA-LNP肿瘤疫苗 3D124 依托 AI 驱动抗原 筛选与自主研发LNP 递送技术，突破国际专利限制，大幅提高递送效率，并在临床前展现出显著肿瘤抑制效果，该产品计划 2026年完成中美双报 IND；靶向 PSMA 的新一代RDC核药 3D1015 对标同类获批产品，展现出1/4 剂量即可实现 ...

Company Overview - Sido Medical Co., Ltd. is an innovative pharmaceutical company focused on oncology and chronic disease treatment, with a vision to "help cancer patients live longer and better" [2] - The company has a product line of 12 innovative drugs with differentiated clinical value, 8 of which are in clinical development or commercialization stages [2] - The first subcutaneous PD-L1 monoclonal antibody, Envida, has been approved for sale by the National Medical Products Administration [2] - The company utilizes its proprietary mRNA research platform and tumor genomic big data AI analysis platform to develop a series of mRNA products [2] - Sido Medical has established capabilities across drug discovery, preclinical research, clinical development, regulatory submission, and commercialization [2] Financial Performance - As of December 31, 2024, Sido Medical reported total revenue of 446 million yuan, a year-on-year decrease of 29.81% [1] - The company recorded a net profit attributable to shareholders of -183 million yuan, an increase of 65.19% year-on-year [1] - The gross profit margin stands at 91.79%, with a debt-to-asset ratio of 42.14% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 1.96 times, with a median of 6.18 times [1] - Sido Medical's P/E ratio is -5.69 times, ranking 132nd in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as: Qingdao Haier Biomedical (0.86), Kingsray Biotechnology (1.43), Dongrui Pharmaceutical (3.06), and Jilin Changlong Pharmaceutical (6.00) [1]